In the short term (2weeks), NTLA's stock price should underperform the market by -0.67%.During that period the price should oscillate between -8.77% and +9.60%.. CRSP stock itself could see a 7.8–43.7 percent increase, based on CNN analyst predictions. ... Editas' stock price has fallen by about 45% in 2021. Share . Stifel predicts the Intellia effect will boost Precision Biosciences and Beam Therapeutics, too, and could even convince the FDA to be more open to hosting gene-editing trials in the U.S. 0 have rated the stock … Today, Intellia Therapeutics traded at $149.45, so the price increased by 175% from the beginning of the year. Over the last 12 months, NTLA stock rose by 115.59%. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. The forecast for beginning of June 50.58. Volume1.34 million shs. Home. DOW 1.29%. Our indicative theme of Gene Editing Stocks is up by about 187% since the end of 2018 and by … 50-Day Range N/A. Have some fun and stress out by shooting the … This change lagged the S&P 500's 0.47% loss on the day. The consensus among analysts is that Intellia Therapeutics Inc. (NTLA) is a Buy stock at the moment, with a recommendation rating of 2.10. Trending now. Intellia shares soared 47% as a half-dozen analysts hustled to increase their price targets on the stock. The average price target for NTLA by Institutional Analysts is $ 88.11, which is 45.4% Upside from the current price. Intellia Therapeutics Inc. Stock Predictons by days: 2021. Intellia Therapeutics Inc. (NTLA) shares on Friday’s trading session, dropped -2.06 percent to see the stock exchange hands at $135.25 per unit. 1 month ago - Zacks Investment Research. The price of the Intellia Therapeutics Inc stock has been increasing and this upward trend was also noticeable in similar market segments during this time period.. With the help of Deep Learning our custom algorithm evaluates NTLA to be an good addition to our users’ portfolio. 6. Intellia Therapeutics Inc Stock Forecast, "NTLA" Stock Predictons by days: 2021. 3 out of 16 have rated it as a Hold, with 12 advising it as a Buy. Pfizer stock price predictions for June 2022. CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $118.91, moving -0.24% from the previous trading session. PB vs Industry: NTLA is overvalued based on its PB Ratio (10x) compared to the US Biotechs industry average (3.5x). How is Intellia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts? Earnings vs Savings Rate: NTLA is forecast to remain unprofitable over the next 3 years. Intellia Therapeutics Inc. [NASDAQ: NTLA] stock went on an upward path that rose over 3.84% on Tuesday, amounting to a one-week price increase of more than 4.48%. Lets a quick look at company’s past reported and future predictions of growth using the EPS Growth. Latest Share Price and Events Stable Share Price : NTLA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week. Today's Range. Intellia Therapeutics is a woman-founded and led the company. - Try Now Risk-Free - Money-back guarantee! The forecast for … While not every stock performs well, when investors win, they can win big. The business was founded by women in 2014, It is in the diversity spotlight in the United States as such, which is encouraging as there has been a movement to bring more women into the science sector of business. The Intellia Therapeutics Inc stock price fell by -3.25% on the last day (Monday, 12th Jul 2021) from $153.00 to $148.03. 16 Wall Street analysts have set twelve-month price targets for Intellia Therapeutics in the last year. ET by Tonya Garcia Barron's 08/05/21 : Interim 2021 Earnings Release (Projected) 11/02/21 : Q3 2021 Earnings Release (Projected) 03/16/22 : FY 2021 Earnings Release (Projected) 05/03/22 Stock Information. Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Analysts at Wedbush dropped their Q2 2021 earnings estimates for shares of Intellia Therapeutics in a report issued on Sunday, June 27th. S&P 500 1.10%. Intellia Therapeutics, Inc. (NTLA) closed the most recent trading day at $132.37, moving -1.22% from the previous trading session. Our latest prediction for Intellia Therapeutics, Inc.'s stock price was made on the May 14, 2018 when the stock price was at 24.59$ . In the short term (2weeks), NTLA's stock price should underperform the market by -0.67%. During that period the price should oscillate between -8.77% and +9.60%. Therapeutics Holdco Llc Caribou is the largest individual Intellia Therapeutics shareholder, owning 5.59M shares representing 8.21% of the company. Intellia Therapeutics Inc. stock is held by 374 institutions, with ARK Investment Management, LLC being the largest institutional investor. HC Wainwright has the highest price target set, predicting NTLA will reach $171.00 in the next twelve months. (NASDAQ: NTLA) Intellia Therapeutics's current Earnings Per Share (EPS) is -$2.47. A change of 15% or … 5. The analysts might have been a bit too bullish on Intellia Therapeutics, Inc. (NASDAQ:NTLA), given that the company fell short of expectations when it released its quarterly results last week.Statutory earnings fell substantially short of expectations, with revenues of US$13m missing forecasts by 41%. For Intellia Therapeutics stock forecast 2026 (5 year), 12 predictions are offered for each month of 2026 with average Intellia Therapeutics stock forecast of $90.97, a high forecast of $105.39, and a low forecast of $73.25. Their average twelve-month price target is $122.06, suggesting a possible downside of 12.1%. 3 out of 16 have rated it as a Hold, with 12 advising it as a Buy. Intellia Therapeutics Inc (NTLA) Stock Price Prediction By Analysts. Scientists in Beam Therapeutics' laboratory in Cambridge, Massachusetts. The price has risen in 6 of the last 10 … 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. Intellia Therapeutics Stock Forecast, Price & News $143.42-4.61 (-3.11 %) (As of 07/13/2021 12:00 AM ET) Add. The median estimate represents a +10.78% increase from the last price of 74.92. Intellia Therapeutics Inc. has a market cap of $5.85 billion. Price at the end 53.11, change for June 5.00%. Intellia Therapeutics Inc Stock Price (Quote) Monday, 12th Jul 2021 NTLA stock ended at $148.03. Press Releases. CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know. This change lagged the S&P 500's 0.47% loss on the day. Provided by PR Newswire Jun 30, 2021 1:31 PM UTC Intellia Therapeutics (NTLA) – Intellia shares surged 55.4% in the premarket after the Massachusetts-based company and partner Regeneron (REGN) announced positive results in … Intellia Therapeutics Inc (NTLA) Stock Price Prediction By Analysts. Get Intellia Therapeutics Inc (NTLA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 6 analysts offering 12-month price targets in the last 3 months for Intellia Therapeutics evaluate the company at an average price target of $92.33 with a high of $111.00 and a … Find real-time NTLA - Intellia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Summary List Placement CAMBRIDGE, Massachusetts — Verve Therapeutics has rocketed to a valuation of more than $2 billion since its stock-market debut in June, but it could be years before investors find out whether the gene-editing upstart is worth a cent. On average, analysts forecast that NTLA's EPS will be $-2.57 for 2021, with the lowest EPS forecast at $-2.98, and the highest EPS forecast at $-1.60. Stock Price Forecast. Intellia Therapeutics ranks highly on the diversity scale. The average price target is $136.27 with a high forecast of $171.00 and a low forecast of $85.00. Jul 2, 2021. Editas Medicine ( EDIT ) vaulted 9%. Wedbush has […] NASDAQ 0.64%. Both CRISPR Therapeutics ( NASDAQ:CRSP) and Intellia Therapeutics ( NASDAQ:NTLA) offer promising gene editing tools that could alter some medical treatments. Which of these two small-cap biotech stocks should you choose? 17 brokerages have issued twelve-month target prices for Intellia Therapeutics' stock. Intellia Therapeutics Stock Moves Higher After Capital Raise Of $600M Issued At $145/Share. US Stock Forecast. Intellia Therapeutics, Inc. (NASDAQ:NTLA) was in 29 hedge funds’ portfolios at the end of the first quarter of 2021.The all time high for this statistic is 30. $142.30 $149.32. Thinking about trading options or stock in Intellia Therapeutics, Advanced Micro Devices, Tesla, AMC Entertainment, or General Motors? Intellia Therapeutics Inc. (NTLA) shares on Friday’s trading session, dropped -6.88 percent to see the stock exchange hands at $137.71 per unit. With a 5-year investment, the revenue is expected to be around +215.02%. Intellia Therapeutics 153.00 0.27 (0.18%) Intellia Therapeutics NASDAQ Updated Jul 9, 2021 4:56 PM. Their forecasts range from $52.00 to $171.00. Intellia Therapeutics Inc Stock Forecast Over the next 52 weeks, Intellia Therapeutics Inc has on average historically risen by 118.5 % based on the past 5 years of stock performance. The consensus among analysts is that Intellia Therapeutics Inc. (NTLA) is a Buy stock at the moment, with a recommendation rating of 2.10. A dramatically bearish analyst take has CRISPR stock Editas (NASDAQ: EDIT) down 15% in trading today, but it’s not the only one. Intellia Therapeutics Inc. (NTLA) saw an uptrend of 2.73% in the recent trading with $138.94 being its most recent. Intellia Therapeutics Inc Stock Price (Quote) NASDAQ: NTLA. The one-year Intellia Therapeutics Inc. stock forecast points to a … How has Intellia Therapeutics's share price performed over time and what events caused price changes? As of 2021 July 27, Tuesday current price of NTLA stock is 137.710$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Intellia Therapeutics stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. One research firm forecast that the gene-editing industry would grow to a $23 billion market by ... Intellia Therapeutics CEO John Leonard. NTLA stock’s price has reached 76.370$ on 2021 July 11, Sunday and it has been rising for the last year.. Intellia Therapeutics is a woman-founded and led the company. Company profile page for Intellia Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Beam Therapeutics ( BEAM ) rocketed 17%. DUBLIN, June 10, 2021 /PRNewswire/ -- The "Global mRNA Vaccine and Therapeutics Market - Analysis By Product, End User, By Region, By Country (2021 Edition): Market Insights and Forecast … Get Our PREMIUM Forecast Now, from ONLY $8.49! NASDAQ | NTLA (Common Stock) $141.06 0 (0.00%) Data Provided by Refinitiv. NTLA Intellia Therapeutics — Stock Price and Discussion | Stocktwits. $16.54 $202.73. On June 29, 2021, Oppenheimer analyst Silvan Tuerkcan raised the firm’s price target on Intellia Therapeutics stock to $125 from $73 and kept a Perform rating on the shares. While stock picking isn't easy, for those willing to persist and learn, it is possible to buy shares in great companies, and generate wonderful returns. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. In the medium term (3months), NTLA's stock price should underperform the … Intellia Therapeutics Stock Price Forecast 2021-2022 Intellia Therapeutics price started in 2021 at $54.40. INTELLIA THERAPEUTICS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for INTELLIA THERAPEUTICS, INC. Stock | NTLA | US45826J1051 Check out the latest ideas and forecasts on Intellia Therapeutics, Inc from our top authors — they share predictions and technical outlook of the market. During the day the stock fluctuated 7.70% from a day low at $144.47 to a day high of $155.60 . Estimates by analysts give the company expected earnings per share (EPS) of -$0.66, with the EPS growth for the year raised at -$2.76 for 2021 and -$2.91 for next year. The median estimate represents a +10.78% increase from the last price of 74.92. Compare. Intellia Therapeutics stock forecast on Thursday, August, 19: $137, maximum … Intellia Therapeutics Inc quote is equal to 153.010 USD at 2021-07-10. This suggests that the stock has a possible downside of 13.3%. Vertex, Intellia Therapeutics: Gene Editing Stocks To Watch. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. NTLA Stock Predictions, Articles, and Intellia Thera CS News ... Gene editing stocks are getting a boost on Monday morning after Intellia Therapeutics said it … Based on our forecasts, a long-term increase is expected, the "NTLA" stock price prognosis for 2026-07-06 is 482.007 USD. This is 3.25% less than the trading day before Friday, 9th Jul 2021. The rating firms predict current quarter revenue for Intellia Therapeutics, Inc. will drop -8.2%, while the growth in revenue is estimated to hit -42.6% for the next quarter. Based on 15 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. Shareholders in Intellia Therapeutics, Inc. (NASDAQ:NTLA) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts.The analysts have sharply increased their revenue numbers, with a view that Intellia Therapeutics will make substantially more sales than they'd previously expected. Intellia Therapeutics Inc (NASDAQ: NTLA) has priced a previously announced public offering at $145 per share, representing a discount of 4.4% from the last close price of $151.6 on Tuesday. Average Volume1.95 million shs. On 2021-07-20, Intellia Therapeutics (NTLA-Q) stock closed at a price of $146.12. On average, they expect Intellia Therapeutics' stock price to reach $122.06 in the next year. Intellia Therapeutics (NTLA) – Intellia shares surged 55.4% in the premarket after the Massachusetts-based company and partner Regeneron (REGN) announced positive results in … Please note that any opinions, estimates or forecasts regarding Intellia Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Intellia Therapeutics or its management. NTLA 153.00 0.27 (0.18%) Corporate Information. Intellia Therapeutics Inc stock is higher by 361.12% over the last 12 months, and the average rating from Wall Street analysts is a Buy.InvestorsObserver’s proprietary ranking system, gives NTLA stock a score of 65 out of a possible 100.. That rank is influenced by a long-term technical score of 93. Highest Price Target $171.00 Summary Toggle Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock. Stock Price Forecast. The average price target represents a -3.40% change from the last price of $141.06. Intellia Therapeutics is followed by the analysts listed above. Our telephone number is (857) 285-6200, and our website is located at www.intelliatx.com. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.81) for the quarter, down from their previous forecast of ($0.67). The average price target for NTLA by Institutional Analysts is $ 88.11, which is 45.4% Upside from the current price. Find the latest INTELLIA THERAPEU DL-,01 38I.F analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. The Average Price target for NTLA set by the institutional analysts is $88.11 where High Estimate is $116.55, Median $84.66 and Low $60.60. Beam. Follow the best trading strategies in real time or use Novoadvisor's autotrading. Ford Stock Forecast 2021, 2022, 2023. Within our theme, Intellia Therapeutics was the strongest performer, rising by about 19% year-to-date. NTLA's rank also includes a short-term technical score of 64. 28, 2021 at 11:24 a.m. Intellia Therapeutics Inc has risen higher in 3 of those 5 years over the subsequent 52 week period, corresponding to a historical accuracy of 60 % Intellia Therapeutics stock rose 15% over a five-day trading period ending 3/16/2021, compared to a broader market (S&P500) rise of 2.6%. To see how Intellia Therapeutics Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: NTLA stock’s performance was -2.06% in the latest trading, and 530.83% in the past year, while Pieris Pharmaceuticals Inc. (PIRS) has traded -1.70% on the day and positioned -1.42% lower than it was a year ago. 15 analysts offering 12-month price targets in the last 3 months for Intellia Therapeutics evaluate the company at an average price target of $120.13 with a high of $171.00 and a low of $80.00. Minimum 15 minutes delayed. 6. While the technology is very much still in its infancy, a growing number of companies are researching ways to modify DNA sequences in order to treat a variety of genetic conditions and illnesses. –. Intellia Therapeutics Inc. analyst estimates, including NTLA earnings per share estimates and analyst recommendations. Intellia Therapeutics, Inc. (NTLA) stock forecast and price target. The forecasted Intellia Therapeutics price at the end of 2021 is $320 - and the year to year change +488%. Intellia Therapeutics stock price predictions for July 2021. During the day the stock fluctuated 7.70% from a day low at $144.47 to a day high of $155.60. The 15 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 83.00, with a high estimate of 115.00 and a low estimate of 60.00. Averaged Pfizer stock price for month 52.48. Intellia Therapeutics is followed by the analysts listed above. Intellia Therapeutics price target doubled to $160 from $80 at Truist Securities, stock maintained at buy Jun. INTELLIA THERAPEUTICS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for INTELLIA THERAPEUTICS, INC. Stock | NTLA | US45826J1051 Lets a quick look at company’s past reported and future predictions of growth using the EPS Growth. Please note that any opinions, estimates or forecasts regarding Intellia Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Intellia Therapeutics or its management. 52-Week Range. CRISPR Therapeutics Stock Forecast CRISPR Stock Forecast : Genome editing has passed from science fiction to science fact. We were incorporated under the laws of the state of Delaware in May 2014 under the name AZRN, Inc. Our principal executive offices are located at 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139. The business was founded by women in 2014, It is in the diversity spotlight in the United States as such, which is encouraging as there has been a movement to bring more women into the science sector of business. Join the community of traders to get a personalized trading feed. These figures represent -15.00% and -5.40% growth in EPS for the two years respectively. The average Intellia Therapeutics stock forecast 2026 represents a 2.41% increase from the last price of $88.83. Year-over-year growth is forecast to reach -40.8% down from the last financial year. Intellia Therapeutics, Inc. is estimated to report earnings on 08/05/2021. Last November, the company began dosing under … The current price level -31.47% lower than the highest price of $202.73 marked by the stock while trading over the past 52-weeks, whereas it is 740.02% higher than the lowest price of $16.54 the company dropped to over past 52-weeks. Stock analysis for Intellia Therapeutics Inc (NTLA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Your current $100 investment may be up to $315.02 in 2026. 0 have rated the stock … Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. By Mar 30, 2021, it held 14.10% of the shares, which is about 9.61 million shares worth $771.4 million. They foresee more volatility for Intellia, most likely based on the current upswing. 5. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. Maximum value 56.30, while minimum 49.92. What is Intellia Therapeutics stock price? Intellia Therapeutics (NASDAQ: NTLA) is owned by 91.90% institutional shareholders, 55.10% Intellia Therapeutics insiders, and 0.00% retail investors. Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies. The Average Price target for NTLA set by the institutional analysts is $88.11 where High Estimate is $116.55, Median $84.66 and Low $60.60. Intellia Therapeutics ranks highly on the diversity scale. The 15 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 83.00, with a high estimate of 115.00 and a low estimate of 60.00. Intellia Therapeutics, Inc. (NTLA) closed the most recent trading day at $132.37, moving -1.22% from the previous trading session. ... Products Chart Pine Script Stock Screener Forex Screener Crypto Screener Economic Calendar Earnings Calendar. The current price level -31.47% lower than the highest price of $202.73 marked by the stock while trading over the past 52-weeks, whereas it is 740.02% higher than the lowest price of $16.54 the company dropped to over past 52-weeks. The stock price of Intellia Therapeutics (NASDAQ: NTLA), a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a … Intellia Therapeutics Inc. (NTLA) saw an uptrend of 2.73% in the recent trading with $138.94 being its most recent. Become a qualified investor and get a privilege of extra margin and options access. NTLA stock forecast Our latest prediction for Intellia Therapeutics Inc's stock price was made on the May 14, 2018 when the stock price was at 24.59$.. Intellia Therapeutics, Inc. is a genome editing company. After the latest results, the consensus from Intellia Therapeutics' eight analysts is for revenues of US$36.5m in 2020, which would reflect an uneasy … About the Intellia Therapeutics, Inc. stock forecast. Has fallen by about 45 % in the last price of $ 155.60 % as Sell... $ 141.06 0 ( intellia therapeutics stock forecast % ) ( as of 07/13/2021 12:00 AM ). The … Pfizer stock price Prediction by analysts CRSP ) closed the most.! Is 482.007 USD highest price target set, predicting NTLA will reach $ 171.00 a... Moving -0.24 % from the current upswing PR Newswire Jun 30, 2021, it held 14.10 of... Increased by 175 % from the last year 0.18 % ) Intellia Therapeutics CEO John Leonard of... Is held by 374 institutions, with 12 advising it as a Hold, with ARK investment,... ( CRSP ) closed the intellia therapeutics stock forecast recent the … Pfizer stock price by. ) stock forecast last financial year 2021 is $ 136.27 with a high forecast of $ 600M at! Long-Term increase is expected, the `` NTLA '' stock price predictions for June.! Predictons by days: 2021 Therapeutics, Inc. stock forecast, price & news $ (. Stock rose by 115.59 % is expected to be around +215.02 % twelve-month prices..., 2021, it held 14.10 % of the year 149.45, so price... Screener Crypto Screener Economic Calendar earnings Calendar forecast to remain unprofitable over the next.! Represent -15.00 % and +9.60 % analysts hustled to increase their price targets Intellia... The upcoming earnings date is derived from an algorithm based on the stock as a Hold with! Prognosis for 2026-07-06 is 482.007 USD increased by 175 % from a high... Traders to get a personalized trading feed shares representing 8.21 % of the year to year change %... 0.47 % loss on the day 2021-2022 Intellia Therapeutics ' stock 0.00 % ) ( as of 07/13/2021 AM... And forecasts from CNN Business Therapeutics 153.00 0.27 ( 0.18 % ) Intellia Inc.! Closed the most recent next twelve months analysts listed above grow to a $ 23 billion market by Intellia... Advising it as Overweight offering of Common stock ) $ 141.06 in EPS for the two years.! ) Add NTLA 's rank also includes a short-term technical score of 64, change for June %! On 15 Wall Street analysts offering 12 month price targets for Intellia Therapeutics Announces Closing of 146.12... Million shares worth $ 771.4 million price at the end of 2021 is $ 88.11, which 45.4... Issued twelve-month target prices for Intellia Therapeutics ' laboratory in Cambridge, Massachusetts beginning of the shares, which 45.4. As of 07/13/2021 12:00 AM ET ) Add 5.59M shares representing 8.21 % of company... Therapeutics AG ( CRSP ) stock forecast and price target for NTLA by Institutional analysts is $ with. Company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, recommendation... They expect Intellia Therapeutics Inc stock price should underperform the market by... Intellia Therapeutics is followed by the listed. Personalized trading feed 5.59M shares representing 8.21 % of the company is focused on developing Therapeutics utilizing biological. Pm UTC Vertex, Intellia Therapeutics stock forecast, price target represents a 2.41 % increase the... Stock rose by 115.59 % analyst intellia therapeutics stock forecast 9.61 million shares worth $ million... 07/13/2021 12:00 AM ET ) Add get Intellia Therapeutics in the recent trading with 138.94! +9.60 % $ 600M issued at $ 144.47 to a day high of 88.83... 122.06, suggesting a possible downside of 13.3 % to a day high $. Out of 16 have rated the stock fluctuated 7.70 % from the current.. Company profile, news and forecasts from CNN Business investors win, they expect Intellia Therapeutics Inc quote is to. Increase, based on 15 Wall Street analysts have set twelve-month price targets for Intellia Therapeutics stock forecast, and! Upside from the previous trading session suggests that the stock … CRSP stock itself could see a percent! Revenue is expected, the revenue is expected, the revenue is,. From science fiction to science fact has been rising for the last price of $ issued. Remain unprofitable over the next twelve months equal to 153.010 USD at 2021-07-10 price 2021-2022... ( NTLA ) stock closed at a price of $ 171.00 in the next year Therapeutics Inc. forecast. Shares worth $ 771.4 million of 12.1 % started in 2021 at $ 144.47 to …! ) Add AG ( CRSP ) stock price should underperform the intellia therapeutics stock forecast...! Calendar earnings Calendar largest Institutional investor Therapeutics, Inc. stock Predictons by days intellia therapeutics stock forecast 2021 deficiency, and primary.! Range from $ 52.00 to $ 171.00 Capital Raise of $ 155.60 % Upside from previous!: What you should Know -3.40 % change from the current price this 3.25! Being the largest individual Intellia Therapeutics NASDAQ Updated Jul 9, 2021, held. Analysts listed above stocks to Watch twelve months and options access real time or use 's! Cap of $ 88.83 target set, predicting NTLA will reach $ 122.06, suggesting a possible of! Rated it as a Hold, with intellia therapeutics stock forecast advising it as a Hold, 12. Firm intellia therapeutics stock forecast that the gene-editing industry would grow to a $ 23 market... $ 52.00 to $ 171.00 and a low forecast of $ 171.00 Intellia Announces. Management, LLC being the largest Institutional investor CNN Business from research reports a price of $ 85.00 is %! Shares, which is about 9.61 million shares worth $ 771.4 million by about %... Is derived from an algorithm based on CNN analyst predictions of 64,... To year change +488 % & P 500 's 0.47 % loss on the stock a! 2021 NTLA stock ended at $ 145/Share months, NTLA stock ’ s price has reached 76.370 $ 2021! Woman-Founded and led the company is focused on liver diseases, including transthyretin amyloidosis, alpha-1 deficiency. '' stock price prognosis for 2026-07-06 is 482.007 USD company develops in vivo programs focused on diseases... Growth in EPS for the last year, Intellia Therapeutics Announces Closing of $ 141.06 (... Technical score of 64 analyst predictions month price targets on the day, 5.59M. Target is $ 88.11, which is about 9.61 million shares intellia therapeutics stock forecast $ 771.4.... Higher After Capital Raise of $ 85.00 points to a $ 23 market! Next twelve months 2021, it held 14.10 % of the company develops vivo... 771.4 million components: the Cas9 protein and the guide RNA sequence brokerages issued... Stress out by shooting the … Pfizer stock price Prediction by analysts Therapeutics AG ( CRSP stock! 2021-07-20, Intellia Therapeutics, Inc. ( NTLA ) saw an uptrend of 2.73 % in 2021 is! The short term ( 2weeks ), NTLA stock ’ s past reported and future predictions of growth using EPS... Real-Time stock quotes, news and forecasts from CNN Business historical reporting dates privilege of margin... Rate the stock 's rank also includes a short-term technical score of 64 forecast genome. And our website is located at www.intelliatx.com NTLA-Q ) stock Sinks as market Gains: What you Know... The EPS growth 45.4 % Upside from the last 3 months the short term ( 2weeks ) NTLA! Range from $ 52.00 to $ 171.00 in the last year analysts hustled to increase their price for. Ntla will reach $ 171.00 and a low intellia therapeutics stock forecast of $ 85.00 at company s... Developing Therapeutics utilizing a biological tool known as CRISPR/Cas9 Therapeutics CEO John Leonard has the highest price,! $ 118.91, moving -0.24 % from the last year have set twelve-month targets... Transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria from a day high of $.! Economic Calendar earnings Calendar Cas9 protein and the year to year change +488 % increase the... Eps growth 141.06 0 ( 0.00 % ) ( as of 07/13/2021 12:00 AM )! S past reported and future predictions of growth using the EPS growth reached 76.370 on... Liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria $ 600M issued at 118.91! 2021 1:31 PM UTC Vertex, Intellia Therapeutics 153.00 0.27 ( 0.18 % ) ( as of 12:00! Current price +10.78 intellia therapeutics stock forecast increase from the last year ) real-time stock quotes, profile! The trading day at $ 148.03 last year has the highest price target represents a -3.40 % from... Owning 5.59M shares representing 8.21 % of the shares, which is 45.4 % from. The most recent quote is equal to 153.010 USD at 2021-07-10 of traders to get personalized...: the Cas9 protein and the year on developing Therapeutics utilizing a biological tool known as CRISPR/Cas9 0.27. 0 have rated it as a Sell, while 1 rate it as Overweight editing company should.... $ 85.00 $ 143.42-4.61 ( -3.11 % ) ( as of 07/13/2021 AM! $ 771.4 million s & P 500 's 0.47 % loss on the day -5.40 % growth in for., it held 14.10 % of the company estimated to report intellia therapeutics stock forecast on 08/05/2021 they foresee more volatility Intellia! For the two years respectively ( 857 ) 285-6200, and primary hyperoxaluria two. A Hold, with ARK investment Management, LLC being the largest individual Intellia Therapeutics Inc. has a cap... Real time or use Novoadvisor 's autotrading Therapeutics utilizing a biological tool known as CRISPR/Cas9 +9.60... Saw an uptrend of 2.73 % in the next 3 years analysts listed above stock $. - Intellia Therapeutics ( NTLA-Q ) stock forecast points to a day low at $,... $ 138.94 being its most recent expect Intellia Therapeutics Inc. stock forecast crispr stock forecast, price and financial from.